Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Chief Executive Officer Lee Tien-Li reported purchasing shares of the company’s common stock in a series of transactions this week. According to a Form 4 filing with the Securities and Exchange Commission, the CEO acquired a total of 20,000 shares for approximately $160,654. The purchases come as the $169 million market cap company maintains a strong liquidity position, with InvestingPro data showing more cash than debt on its balance sheet.
The purchases occurred over three days. On September 10, 2025, Lee bought 9,000 shares. This was followed by another purchase of 6,000 shares on September 11, 2025, and 5,000 shares on September 12, 2025. The prices paid for these shares ranged from $7.821 to $8.5031. With analyst price targets ranging from $19 to $50, these insider transactions merit attention. Track insider trading patterns and access 8 additional key insights with InvestingPro.
Following these transactions, Lee directly owns 1,533,384 shares of Aardvark Therapeutics , Inc. In addition, Lee indirectly owns 1,474,028 shares through a spouse. The company maintains a healthy current ratio of 14, indicating strong short-term financial stability despite ongoing cash burn.
In other recent news, Aardvark Therapeutics announced promising results from a preclinical study of its investigational drug ARD-201, which showed a 19% reduction in body weight in diet-induced obese mice after 30 days. This study also indicated that ARD-201 could help manage weight regain when used with the drug tirzepatide. In terms of analyst ratings, Cantor Fitzgerald reiterated its Overweight rating and maintained a $50.00 price target for Aardvark Therapeutics, emphasizing the company’s market valuation and the potential success of its Phase 3 study. RBC Capital, however, lowered its price target from $20.00 to $19.00, citing delays in the company’s clinical plans, specifically the postponement of a Phase III trial for its ’101 drug in Prader-Willi syndrome to the third quarter of 2026. Meanwhile, H.C. Wainwright initiated coverage with a Buy rating and set a price target of $40.00, highlighting Aardvark’s novel approach to treating obesity and hyperphagic conditions. These developments reflect a mixed outlook among analysts, with some expressing optimism about the company’s potential and others noting concerns about timeline delays.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.